Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Work In Process (2023 - 2025)

Historic Work In Process for Krystal Biotech (KRYS) over the last 3 years, with Q4 2025 value amounting to $15.2 million.

  • Krystal Biotech's Work In Process rose 4171.09% to $15.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $15.2 million, marking a year-over-year increase of 4171.09%. This contributed to the annual value of $15.2 million for FY2025, which is 4171.09% up from last year.
  • Per Krystal Biotech's latest filing, its Work In Process stood at $15.2 million for Q4 2025, which was up 4171.09% from $15.8 million recorded in Q3 2025.
  • Krystal Biotech's Work In Process' 5-year high stood at $15.8 million during Q3 2025, with a 5-year trough of $3.2 million in Q4 2023.
  • In the last 3 years, Krystal Biotech's Work In Process had a median value of $8.9 million in 2025 and averaged $9.7 million.
  • Per our database at Business Quant, Krystal Biotech's Work In Process soared by 23529.96% in 2024 and then skyrocketed by 3942.38% in 2025.
  • Krystal Biotech's Work In Process (Quarter) stood at $3.2 million in 2023, then surged by 235.3% to $10.7 million in 2024, then soared by 41.71% to $15.2 million in 2025.
  • Its Work In Process was $15.2 million in Q4 2025, compared to $15.8 million in Q3 2025 and $15.3 million in Q2 2025.